Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
18 August 2021 | Story ANDRÉ DAMONS | Photo ANDRÉ DAMONS
Dr Osayande Evbuomwan, a Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, always wanted to specialise in an area of medicine that was novel, innovative, intriguing and involved a lot of opportunities for groundbreaking research
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, Faculty of Health Sciences, at the University of the Free State (UFS) always wanted to specialize in an area of medicine that was novel, innovative, intriguing and involved many opportunities for groundbreaking research.

This passionate medical man, who joined the UFS in 2019, is behind his department using Lutetium 177 PSMA (Lu-177 PSMA) therapy to treatment metastatic castrate resistant prostate cancer (MCRPC) – an advanced stage prostate cancer. 
The UFS and the Free State province can now join other South African universities, like the University of Pretoria, University of the Witwatersrand, and other provinces in using this method to treat MCRPC patients. 

Built for this job

Dr Evbuomwan explains nuclear medicine is a medical specialty that involves the use of unsealed sources of radiation in the form of radioisotopes for the diagnosis and treatment of various disease conditions including cancers.
“It’s novelty and opportunity for research and ability to diagnose and treat disease conditions in one specialty attracted me to this field. I always wanted to be a doctor. I see it as a calling. It was also something my mum discovered while I was growing up as a child. In my next life, I would choose to be a medical doctor again,” he says.

“I was built for this job and it is always my joy to have the opportunity to carry out my work. We have been well-trained for this; we support all our skills with prayers. We try to give our patients the very best,” says Dr Evbuomwan, who is originally from Benin City, Edo state, Nigeria. 

After graduating as a nuclear medicine specialist from Wits University, Dr Evbuomwan moved to the City of Roses after a work opportunity opened. He saw it as an opportunity to showcase his talents.

“I have been privileged to receive training in this treatment during my residency training at Wits. I treated a few of these patients during my training and the results were amazing. The University of Pretoria has also been involved with this treatment, with some amazing results that are recognised worldwide. 

“This was enough to convince me to push for our department to also join the powerhouses and offer this treatment to patients who need it. With the influence of a very understanding head of department, Dr Gerrit Engelbrecht, we have been successful in pushing for the commencement of this treatment at our facility,” says Dr Evbuomwan.

Important treatment
According to him, the availability and expertise of Lutetium 177 PSMA (Lu-177 PSMA) therapy to treat MCRPC is very important for the Free State and the UFS, as it is able to offer an option for patients who do not qualify for available conventional treatment and/or who have failed the first line of conventional treatment. 

“In the majority of patients this treatment offers improved quality of life, disease-free progression and improved overall survival. It also alleviates the constant bone pains these patients have to go through daily. To be able to offer this treatment puts the university and the province on the map alongside other top institutions in and outside the country. It also offers opportunity for research,” says Dr Evbuomwan.

He believes with a PET/CT camera for proper staging of these patients with cancer the UFS would be able to expand the treatment of patients suffering from this deadly illness. Currently the university does not possess such a camera and has to use lesser methods in identifying the right patients for this therapy.

News Archive

UFS extends footprint abroad
2015-12-14

In its constant pursuit of research excellence, the UFS has this year performed well in mainly two areas.

Apart from the research done by the UFS on national level, e.g. the involvement of its researchers with the SKA telescope, the pioneering work they do with the satellite tracking of giraffes, as well as research on trauma, forgiveness and reconciliation – to name but a few of the research areas, the university also has a research focus abroad.

Japan, Europe, America and Botswana. These are just some of the places where academics from the university are involved in research abroad.

Japan

Dr Dirk Opperman, Senior Lecturer at the Department of Microbial, Biochemical and Food Biotechnology, and Carmien Tolmie, a PhD student in the same department, visited the Okinawa Institute of Science and Technology in Onna, Japan, during November and December 2014. During the visit, experiments were performed in the Microbiology and Biochemistry of Secondary Metabolite Unit of Dr Holger Jenke-Kodama.

This formed part of a larger NRF-funded project on carcinogenic toxins produced in certain Aspergillus fungi. These fungi infect food and feedstuff and are a big concern in developing countries because it may lead to severe economic losses. The research ultimately aims to find inhibitors to block the production of these fungal toxins.



Europe and America

In 2012, an international network was established in the frame of the FP7-PEOPLE-2011-IRSES programme, called hERG-related risk assessment of botanicals (hERGscreen). The South African group included Dr Susan Bonnet and Dr Anke Wilhelm, both from the UFS Department of Chemistry.

Extracts from more than 450 South African plant species have been investigated systematically to assess the potential cardiotoxic risk of commonly consumed botanicals and supplements. The idea of the project, funded by the European Commission, is to identify safety liabilities of botanicals.

Other international partners included the University of Innsbruck, National and Kapodistrian University of Athens, Biomedical Research Foundation of the Academy of Athens, University of Basel, University of Vienna, University of Florida, Universidade Federal do Rio Grande do Sul, Universidade Federal de Santa Catarina.

Botswana

A memorandum of understanding was signed between the UFS and Botho University in Botswana in September 2015, which will be valid for three years.

The agreement, includes student and staff exchange programmes, collaborative research, teaching and learning and community engagement activities, sharing of results, and PhD/ MPhil guidance.

Young researchers

Another research focus of the UFS is the development of its young researchers. In 2015, the UFS has delivered 13 Y-rated researchers. Ten of the researchers are from the Faculty of Natural and Agricultural Sciences and three from the Faculty of the Humanities. Three of them received an Y1 rating from the NRF.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept